_Meet our ongoing investments
Our mission is simple – provide our investors with access to the most promising and impactful life sciences technologies.
We focus mostly on early-stage companies developing novel therapies in Europe and the US. Within therapeutics, we remain agnostic in terms of indication and modality, but value highly differentiated companies targeting clear unmet needs.

Cell depleting therapies for fibrotic diseases
USA
USA

Disruptive RNA editing therapies
USA
USA

Clinical stage precision immunotherapy for cancer
USA
USA

Next-generation CNS Cancer drugs
Switzerland
Switzerland

RNA therapeutics for liver disease
UK
UK

Reprogramming Macrophages for the treatment of cancer
Scotland
Scotland

Gene Therapy Platform
USA
USA

First shigella and ETEC vaccine
Austria
Austria

Life sciences Accelerator
Austria
Austria

Targeting tissue degeneration
Austria
Austria

Hearing loss therapies
USA
USA

Healthcare review platform
UK
UK

New drugs for CNS disorders
Spain
Spain

Deep Brain Stimulation therapies
Switzerland
Switzerland